, Melanoma is a common and deadly tumor that frequenfiy metastasizes to the central nervous system (CNS), resulting in a median survival durafion of 3.7 month and refractoriness to conventional therapy. A key transcripfionalfactor, signal transducer and activator of transcription (STAT)-3, drives the components of melanoma and is over expressed in 80% of melanoma CNS metastases,. Phosphorylated STAT-3 propagates turhorigenesis by enhancing proliferation, angiogenesis, invasion, metastasis, and mmunosuppression. We developed WP1066, a potent orally administered inhibitor of STAT-3 that displays marked efficacy against established intracerebral melanoma in vivo. The mechanism of WP1066's activity is a combinafion of direct melanoma cytotoxicity and immune cytotoxic clearance. In this proposed study, we will further clarify the mechanisms of activity and targets of WP1066 using murine melanoma models of metastasis to identify biomarkers and potenfial selecfioh criteria for a Phase l/ll cliriical trial. This study will focus on whether over expression of phosphorylated STATS in the parenchymal tumors of patients with stage IV melanoma is predictive of CNS metastasis and whether this over expression is an independent predictor of survival. We have demonstrated that a significant mechanism of WP1066's activity is enhancement of CD8+ T-cell effector resporises and inhibifion of regulatory T cells: Immunotherapy with both interferon-alpha and interieukin-2 is used for melanoma, but the response rates remain low. We will further determine vyhether WP1066 Can markedly improve these immunotherapy modalities in in vivo murine model systems. These studies will lay the groundwork for a potenfial clinical trial of WP1066 as an immunomodulator. These following specific aims are the basis for conducting these studies: 1) Evaluate mechanisms of activity of WP1066 and identify biological markers for a clinical trial of WP1066;2) Evaluate the natural history of p-STAT-3 expression in patients with melanoma and determine whether WP1066 can impact these processes in in vivo murine models to clarify clinical trial design;3) Establish whether reversing immune suppression with WP1066 is synergisfic with other immunotherapies for melanoma. These translational studies will bring to the forefront a novel therapeufic that has real potential to improve the survival of patients with melanoma havirig CNS metastatic disease, a major unmet clinical need.

Public Health Relevance

Stage IV melanoma patients with CNS metastasis have few therapeutic options and are a greatly underserved population. Our intenfion is to implement clinical trials with WP1066 in melanoma patients with established CNS metastasis, determine if we can predict which stage IV melanoma pafients are at risk for CNS metastasis, arid to develop STAT-3 inhibitors as potent immune modulators to be potenfially used in combination with other approved immune therapeutics that have limited clinical efficacy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA093459-10
Application #
8728572
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
10
Fiscal Year
2014
Total Cost
$182,819
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
(2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50:668-681
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
Kim, Sun-Hee; Roszik, Jason; Cho, Sung-Nam et al. (2018) The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma. Clin Cancer Res :
Zhang, Tongwu; Choi, Jiyeon; Kovacs, Michael A et al. (2018) Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes. Genome Res 28:1621-1635
Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461
Cascone, Tina; McKenzie, Jodi A; Mbofung, Rina M et al. (2018) Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27:977-987.e4
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Teerlink, Craig C; Huff, Chad; Stevens, Jeff et al. (2018) A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma. J Natl Cancer Inst :
Bezrookove, Vladimir; Nosrati, Mehdi; Miller 3rd, James R et al. (2018) Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clin Cancer Res 24:4119-4125

Showing the most recent 10 out of 290 publications